You can buy or sell NEOS and other stocks, options, ETFs, and crypto commission-free!
Neos Therapeutics, Inc. Common Stock, also called Neos Therapeutics, is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Read More Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX.
Grand Prairie, Texas
52 Week High
52 Week Low
Simply Wall StMar 25
What Kind Of Investor Owns Most Of Neos Therapeutics, Inc. (NASDAQ:NEOS)?
A look at the shareholders of Neos Therapeutics, Inc. (NASDAQ:NEOS) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Warren Buffett said that he likes ‘a business with enduring competitive advantages that is run by able and owner-oriented people’. So it’s nice to see some insider ownership, because it may suggest that management is owner-oriented. Neos Therapeutics is ...
Guru FocusMar 18
Neos Therapeutics Inc (NEOS) Files 10-K for the Fiscal Year Ended on December 31, 2018
Neos Therapeutics Inc (NASDAQ:NEOS) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Neos Therapeutics Inc is a pharmaceutical company, engaged in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder using its drug delivery technologies.
Seeking AlphaMar 14
Neos Therapeutics, Inc. (NEOS) CEO Jerry McLaughlin on Q4 2018 Results - Earnings Call Transcript
Neos Therapeutics, Inc. (NASDAQ:NEOS) Q4 2018 Results Conference Call March 14, 2019 9:30 AM ET Company Participants Richard Eisenstadt - CFO Jerry McLaughlin - CEO Conference Call Participants Louise Chen - Cantor Fitzgerald Jason Butler - JMP Securities Bill Maughan - Cowen and Company Gary Nachman - BMO Capital Markets Jacob Hughes - Wells Fargo Operator Good morning. And welcome to the Neos Therapeutics' Fourth Quarter and Full Year 2018 Financial Results Conference Call. Today's call is bein...
-$0.28 per share
-$0.23 per share